Trade Bristol-Myers Squibb Co (Extended hours) - BMY CFD
Add to favourite- Summary
- Historical Data
Trading сonditions
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
Key Stats
| Prev. Close | 57.58 |
| Open | 57.58 |
| 1-Year Change | 13.53% |
| Day's Range | 57.3 - 58.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | 57.60 | 0.00 | 0.00% | 57.60 | 57.64 | 57.60 |
| Dec 17, 2024 | 57.59 | 1.78 | 3.19% | 55.81 | 57.72 | 55.36 |
| Dec 16, 2024 | 55.62 | 0.50 | 0.91% | 55.12 | 56.90 | 54.73 |
| Dec 13, 2024 | 55.49 | -0.74 | -1.32% | 56.23 | 56.34 | 54.95 |
| Dec 12, 2024 | 56.23 | -0.40 | -0.71% | 56.63 | 57.15 | 55.87 |
| Dec 11, 2024 | 56.57 | -1.43 | -2.47% | 58.00 | 58.09 | 56.56 |
| Dec 10, 2024 | 58.09 | -0.53 | -0.90% | 58.62 | 58.62 | 57.75 |
| Dec 9, 2024 | 58.67 | -0.14 | -0.24% | 58.81 | 59.71 | 58.64 |
| Dec 6, 2024 | 59.29 | 0.50 | 0.85% | 58.79 | 59.47 | 58.63 |
| Dec 5, 2024 | 58.80 | 0.62 | 1.07% | 58.18 | 59.17 | 58.16 |
| Dec 4, 2024 | 58.30 | -0.22 | -0.38% | 58.52 | 58.69 | 57.52 |
| Dec 3, 2024 | 58.63 | -1.07 | -1.79% | 59.70 | 60.02 | 58.57 |
| Dec 2, 2024 | 59.75 | 0.69 | 1.17% | 59.06 | 60.01 | 58.84 |
| Nov 29, 2024 | 59.05 | -0.22 | -0.37% | 59.27 | 59.46 | 58.89 |
| Nov 27, 2024 | 59.20 | 0.42 | 0.71% | 58.78 | 59.45 | 58.55 |
| Nov 26, 2024 | 58.65 | -0.13 | -0.22% | 58.78 | 58.95 | 57.99 |
| Nov 25, 2024 | 58.71 | -0.59 | -0.99% | 59.30 | 60.58 | 58.57 |
| Nov 22, 2024 | 58.67 | 1.02 | 1.77% | 57.65 | 58.86 | 57.42 |
| Nov 21, 2024 | 58.18 | 0.20 | 0.34% | 57.98 | 58.42 | 57.36 |
| Nov 20, 2024 | 57.83 | -0.47 | -0.81% | 58.30 | 58.61 | 57.58 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Bristol-Myers Squibb Company profile
What is Bristol-Myers Squibb Co.?
The Bristol-Myers Squibb Company is an international biopharmaceutical company specialising in discovering, developing and delivering innovative biopharmaceutical products and medicines to patients who suffer from serious diseases. Bristol-Myers Squibb provides medicines to help people fight cancer, hepatitis B and C, cardiovascular disease, HIV and AIDS. The company supplies its products to retail and wholesale pharmacies, governmental entities, and hospitals throughout the world.
What’s the history behind the company?
1858 – The Squibb corporation is founded by Edward Robinson Squibb in New York.
1887 – The Clinton Pharmaceutical company i purchased by William McLaren Bristol and John Ripley Myers. Two years later they rename it as “Bristol, Myers and Company”, and later, following Myers death in 1899 as the “Bristol-Myers Corporation”.
1903 – Sal Hepatica, a laxative salt is developed and released marking the first product for the company.
1943 – Acquisition of Cheplin Biological Laboratories, Bristol laboratories in 1945 creating antibiotics, is met with competition from Squibbs.
1989 – Bristol-Myers merges with Squibb to form Bristol-Myers Squibb, creating one of the world’s largest pharmaceutical companies.
1998 – Development of Excedrin Migraine, one of the first migraine medications available without a prescription in the US.
2004 – Bristol-Myers Squibb pays $150 million in a settlement for accounting fraud, the company does not admit or deny guilt. In 2006, the company is hit again by charges and pays $2.1 million to the Federal Trade Commission.
2008 – The company undertakes a number of partnerships, including therapy for cardiovascular diseases with KAI pharmaceuticals, cancer therapies with Kosan, and two novel therapies for cancer with Exelixis. These collaborations continue into 2009 with more added.
2010 – Lamberto Andreotti took over as CEO of Bristol-Myers Squibb. By 2012, the company’s net sales reach $17.6 billion.
2015 – Dr. Giovanni Caforio becomes the head of the company.
About the company
Bristol-Myers Squibb operates worldwide with locations such as Asia, including China and Japan, Southeast Asia in Bangalore India, across Europe in Belgium, England, France, Ireland and Italy, and North America. This includes a number of research and development facilities, vital to the creation of new pharmaceutical products.
Across its facilities, the company employs approximately 23,700 people. To date, Dr. Giovanni Caforio is the Chairman and CEO of the company with Charles Bancroft as CFO.
The company has numerous awards and achievements, including 2018 Best-of-the-Best Corporations for Inclusion by National Business Inclusion Consortium, Fortune’s World’s Most Admired Companies, Dow Jones' 2017 North American Index of Leading Sustainable Companies, and Forbes America’s Best Employers for 2016.
Key Statistics
- Revenue in 2017 – $20.78 billion
- Net income in 2017 – $975 million
- Total assets in 2017 – 33.55 billion
- Total equity in 2017 – 11.85 billion
Major acquisitions
- Adnexus Therapeutics – 2007
- Kosan Biosciences – 2008
- Medarex – 2009
- ZymoGenetics – 2010
- Amira Pharmaceuticals – 2011
- Inhibitex Inc. – 2012
- Amylin Pharmaceuticals and AstraZeneca – 2018
- iPierian – 2014
- Flexus Biosciences – 2015
- Cardioxyl – 2015
- Padlock Therapeutics – 2016
- Cormorant Pharmaceuticals – 2016
- IFM Therapeutics – 2017
Where is Bristol-Myers Squibb Co. traded?
Bristol-Myers Squibb is traded on the New York Stock Exchange (NYSE) under the ticker BMY. It is also a component of the S&P 100 and S&P 500. Trade the latest Bristol-Myers Squibb share price with Capital.com, explore the most up-to-date BMY charts, and delve into this pharmaceutical company.
| Industry: | Pharmaceuticals (NEC) |
Route 206 And Province Line Road
PRINCETON
NEW JERSEY 08543
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com